| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-27 subunit alpha, IL-27 subunit alpha, IL-27-A, IL27-A, Interleukin-30, p28, IL27, IL27A, IL30 |
| Entrez GeneID | 246778 |
| WB Predicted band size | 27.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | This IL27 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 126-154 amino acids from the Central region of human IL27. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与IL-27抗体相关的代表性文献示例(注：内容为模拟概括，实际文献需通过学术数据库核实)：
---
1. **标题**: *Therapeutic targeting of IL-27 signaling in autoimmune diseases*
**作者**: Smith A, et al.
**摘要**: 研究证明抗IL-27单克隆抗体可通过抑制Th17细胞分化和促进调节性T细胞功能，缓解实验性自身免疫性脑脊髓炎(EAE)模型的神经炎症，提示其在多发性硬化等疾病中的治疗潜力。
---
2. **标题**: *IL-27 blockade enhances antitumor immunity by reprogramming CD8+ T cell metabolism*
**作者**: Wang B, et al.
**摘要**: 在小鼠黑色素瘤模型中，抑制IL-27信号通路可增强CD8+ T细胞的线粒体代谢活性，提高肿瘤微环境中的T细胞杀伤能力，联合PD-1抗体后显著抑制肿瘤生长。
---
3. **标题**: *IL-27 modulates mucosal immunity in inflammatory bowel disease via epithelial cell crosstalk*
**作者**: Chen L, et al.
**摘要**: 发现IL-27抗体可减少肠道上皮细胞释放促炎因子(如IL-1β)，并通过STAT1/IRF1通路修复肠道屏障功能，在结肠炎模型中减轻炎症和黏膜损伤。
---
**建议**：实际引用时请通过PubMed或Google Scholar搜索关键词“IL-27 antibody”、“anti-IL-27 therapy”等获取最新文献，并优先选择高影响力期刊(如Nature Immunology、Journal of Experimental Medicine)或权威团队的研究。
IL-27 is a heterodimeric cytokine belonging to the IL-12 family, composed of p28 and Epstein-Barr virus-induced gene 3 (EBI3) subunits. Primarily secreted by antigen-presenting cells (e.g., dendritic cells, macrophages), it signals through a receptor complex of IL-27Rα (WSX-1) and gp130. activating JAK-STAT, MAPK, and PI3K pathways. IL-27 exhibits dual immunoregulatory roles: promoting Th1 differentiation and cytotoxic T-cell activity while suppressing Th2. Th17. and regulatory T-cell responses. This balance positions IL-27 as a key modulator in infections, autoimmune diseases, and cancer.
IL-27-targeting antibodies are emerging as therapeutic tools. Neutralizing antibodies (antagonists) aim to block IL-27 signaling in conditions like inflammatory bowel disease or multiple sclerosis, where its pro-inflammatory effects dominate. Conversely, agonist antibodies mimicking IL-27 activity are explored to enhance anti-tumor immunity or control chronic infections. Preclinical studies highlight their potential in melanoma and viral models, but challenges remain, including optimizing specificity and minimizing off-target effects. Clinical trials are in early phases, focusing on safety and efficacy. Further research is needed to clarify context-dependent roles of IL-27 and refine antibody-based strategies for precision immunotherapy.
×
